Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3327-3334
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3327
Table 1 Baseline demographic and clinical characteristics of the inflammatory bowel disease patients n (%)
DiagnosisCD (n = 146)UC (n = 73)
Gender
Male:female61:8530:43
Age at diagnosis
< 40 (A1):40 (A2)111:3538:35
Disease location CD
Terminal ileum (L1)30 (20.5)
Colon (L2)42 (28.8)
Ileocolon (L3)65 (44.5)
Upper GI (L4)9 (6.2)
Disease behavior
NS/NP (B1)53 (36.3)
Stricturing (B2)45 (30.8)
Penetrating (B3)48 (32.9)
Perianal disease
Yes:no38:108 (26.1)
Disease location UC
Pancolitis38 (52.1)
Non-pancolitis35 (47.9)
Disease activity
Moderate/severe28 (19.2)15 (20.5)
Mild/Remission118 (80.8)58 (79.5)
Surgery because of IBD
Yes:no48:98 (32.9)0:73 (0)
Chronic steroid use
Yes:no26:120 (17.8)10:63 (13.7)
Side effects of medication
Yes:no43:103 (29.4)18:55 (24.6)
Azathioprine
Yes:no138:8 (94.5)44:29 (60.3)
Table 2 Primer sequences used to identify the G238C, G460A, and A719G polymorphisms of the thiopurine-methyl-transferase gene
NameSequenceProduct size
P2W reverse5’ GTA TGA TTT TAT GACGGT TG 3’254
P2M reverse5’ GTA TGA TTT TATGCA GGT TTC 3’
P2C forward5’ TAA ATAGGAACC ATCGGA CAC 3’
460 forward5’ TCC CCA AAT CAT AAC AGA GTG 3’375
460 reverse5’ CTAGAACCCAGAAAAAGTATAG3’
719 forward5’ CGT TGT CTT GAG AAG GTT GA 3’175
719 reverse5’ CAT TAC ATT TTC AGG CTT TAG CAT A 3’
Table 3 Allelic frequencies of C238G, G460, and A719G in patients with inflammatory bowel disease
PolymorphismCHzHTzRHznAllelic frequencyχ2P-value
CD
C238GC:CC:GG:GCG
Observed141501460.980.020.040.83
Expected14150
G460A/A719GG:G/A:AG:A/A:GA/A:G/GG/AA/G
Observed137901460.970.030.140.70
Expected13790
A719GA:AA:GG:GAG
Observed1281801460.940.060.630.42
Expected128161
UC
C238GC:CC:GG:GCG
Observed7120730.990.010.010.90
Expected7120
G460A/A719GG:G/A:AG:A/A:GA/A:G/GG/AA/G
Observed7030730.980.020.030.85
Expected7030
A719GA:AA:GG:GAG
Observed6670730.950.050.180.66
Expected6670
Table 4 Analysis of thiopurine-methyl-transferase gene polymorphisms in patients with inflammatory bowel disease n (%)
TPMT SNPCHzHTzRHzP-value
C238GC:CC:GG:G
CD (n = 143)137 (95.8)6 (4.2)00.722
UC (n = 71)69 (97.2)2 (2.8)0
G460A/A719GG:G/A:AG:A/A:GA/A:G/G
CD (n = 126)118 (93.7)8 (6.3)00.750
UC (n = 69)66 (95.7)3 (4.3)0
A719GA:AA:GG:G
CD (n = 135)122 (90.4)13 (9.6)00.612
UC (n = 71)66 (93.0)5 (7.0)0
Table 5 Association between the thiopurine-methyl-transferase polymorphisms and adverse effects in patients with inflammatory bowel disease n (%)
C238G
G460A/A719G
A719G
Adverse effectCHzHTzCHzHTzCHzHTz
Crohn’s disease35/143 (24.5)30/126 (23.8)33/135 (24.4)
Myelosuppression000000
Neutropenia3 (2.1)02 (1.6)02 (1.5)0
Flu-like symptoms3 (2.1)03 (2.4)03 (2.2)0
Nausea/vomiting12 (8.4)09 (7.1)1 (0.8)11 (8.1)1 (0.7)
Allergy/dermatitis1 (0.7)02 (1.6)02 (1.5)0
Hepatotoxicity5 (3.5)1 (0.7)5 (4.0)05 (3.7)0
Amylase/lipase elevation6 (4.2)2 (1.4)6 (4.7)03 (2.2)4 (2.9)
Pancreatitis1 (0.7)1 (0.7)2 (1.6)02 (1.5)0
Ulcerative colitis14/71 (19.7)18/68 (26.5)14/71 (19.7)
Myelosuppression000000
Neutropenia000000
Flu-like symptoms)1 (1.4)01 (1.5)01 (1.4)0
Nausea/vomiting4 (5.6)03 (4.4)03 (4.2)0
Allergy/dermatitis3 (4.2)2 (2.8)3 (4.4)02 (2.8)0
Hepatotoxicity000000
Amylase/lipase elevation2 (2.8)1 (1.4)3 (4.4)03 (4.2)0
Pancreatitis01 (1.4)1 (1.5)01 (1.4)0